FOXO4-DRI
/ D-amino-acid retro-inverso peptide designed to interfere with FOXO4-p53 interactionALIAS · FOXO4-D-Retro-Inverso
Terms in this page you can click for a plain-English popup: , , , , , , , .
Proposed as a senolytic based on 2017 preclinical work. Reports from one group dominate. No human trials exist.
FOXO4-DRI is a D-amino-acid retro-inverso peptide designed to block the interaction between FOXO4 and p53 in senescent cells. The hypothesis, originating from the Peter de Keizer laboratory, is that disrupting this interaction allows apoptosis of senescent cells, producing a senolytic effect.
No human trials have been published. Published evidence is limited to preclinical mouse studies from the originating group. Independent replication and human pharmacokinetic/pharmacodynamic data are absent.
No human safety data. Senolytic strategies as a class raise theoretical concerns about normal-cell off-target effects; FOXO4-DRI-specific long-term safety is not characterized.
Regulatory status
- FDA status:
- Not FDA-approved
FOXO4-DRI is a striking example of single-lab-dominant preclinical data reaching the research-chemical market before independent replication. Marketing claims about geroprotective effects far outrun the actual evidence base.